AptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy.
The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs.
“This approval and successful market launch further demonstrate the broad potential for Aptar’s patient-friendly drug delivery solutions and services offerings which help our pharmaceutical customers address unmet healthcare needs,” president and CEO of Aptar Stephan Tanda said in a news release. “We are pleased to offer a broad portfolio of innovative technologies and wide array of services to meet the highest quality standards of the pharmaceutical industry.”
Aptar’s Unidose Liquid System is a single-use, one-step nasal delivery device that is designed to be administered by a non-healthcare professional to someone during or after a seizure. The patient or caregiver presses a small plunger on the bottom of the device that releases the drug in a single spray into the nostril where the nasal mucosa quickly absorbs the drug.
“The launch of our Unidose System on the first and only U.S. FDA approved nasal rescue treatment for seizure activity once again demonstrates Aptar Pharma’s ability to help out customers develop and launch complex treatments,” president of Aptar Pharma Gael Touya said. “When we combine our nasal systems’s capabilities with Noble’s training devices for on boarding, we bring added value to our customers and further convenience for patients and consumers worldwide.”
